The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines

被引:11
作者
Bahi, Morwan [1 ]
Walmsley, Russell S. [5 ]
Gray, Andrew R. [2 ]
Young, David [3 ]
Hobbs, Catherine E. [1 ]
Aluzaite, Kristina [1 ]
Schultz, Michael [1 ,4 ]
机构
[1] Univ Otago, Dunedin Sch Med, Dept Med, POB 913, Dunedin 9054, New Zealand
[2] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand
[3] Southern Dermatol Locums Ltd, Dunedin, New Zealand
[4] Dunedin Publ Hosp, Southern Dist Hlth Board, Gastroenterol Unit, Dunedin, New Zealand
[5] North Shore Hosp, Dept Gastroenterol, Waitemata Dist Hlth Board, Auckland, New Zealand
关键词
incidence; inflammatory bowel disease; New Zealand; non-melanoma skin cancer; thiopurine; TRANSPLANT RECIPIENTS; EPIDEMIOLOGY; TRENDS; POPULATION; MANAGEMENT; MELANOMA;
D O I
10.1111/jgh.14041
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew Zealand (NZ) has one of the highest rates of non-melanoma skin cancers (NMSCs) in the world. Thiopurine use in inflammatory bowel disease (IBD) patients has been shown to increase NMSC risk. This study aimed to investigate the possible increase of NMSC risk in thiopurine-treated IBD patients in NZ despite the high background rate. MethodsInflammatory bowel disease patients treated with thiopurines and healthy controls were recruited across two different latitude centers in NZ. Consented participants completed a questionnaire to identify additional risk factors and were examined for suspicious skin lesions. These were photographed, and the pictures were evaluated by a dermatologist. Data were compared between centers and between groups with NMSC incidence and thiopurineassociated relative risks estimated. ResultsOne hundred seventy-one thiopurine-exposed IBD patients and 201 controls were recruited. Twenty seven of 390 photographs (26 participants) showed suspicious lesions (17 exposed, 9 controls) as determined by the dermatologist. Estimated NMSC incidence was 24.7-34.3/1000patient-years (thiopurine-exposed, depending on classification of unconfirmed suspicious lesions) and 7-14/1000patient-years (control). The relative risk of NMSC among thiopurine exposed was 2.38-2.97 (P0.014), which remained significant after individually adjusting for potential confounders. We estimated the NMSC risk to increase 5.4-6.6% per 6months of thiopurine use (P<0.001). Low compliance in avoiding NMSC risk factors in the exposed group was observed. ConclusionsWe found a twofold to threefold increase in NMSC incidence in IBD patients treated with thiopurines in NZ, despite the high background incidence rate.
引用
收藏
页码:1047 / 1052
页数:6
相关论文
共 33 条
[1]   Incidence, Management, and Course of Cancer in Patients with Inflammatory Bowel Disease [J].
Algaba, Alicia ;
Guerra, Ivan ;
Marin-Jimenez, Ignacio ;
Quintanilla, Elvira ;
Lopez-Serrano, Pilar ;
Concepcion Garcia-Sanchez, Maria ;
Casis, Begona ;
Taxonera, Carlos ;
Moral, Ignacio ;
Chaparro, Maria ;
Martin-Rodriguez, Daniel ;
Dolores Martin-Arranz, Maria ;
Mancenido, Noemi ;
Menchen, Luis ;
Lopez-Sanroman, Antonio ;
Castano, Angel ;
Bermejoa, Fernando .
JOURNAL OF CROHNS & COLITIS, 2015, 9 (04) :326-333
[2]   Epidemiology and risk factors for IBD [J].
Ananthakrishnan, Ashwin N. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2015, 12 (04) :205-217
[3]   European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies [J].
Annese, Vito ;
Beaugerie, Laurent ;
Egan, Laurence ;
Biancone, Livia ;
Bolling, Claus ;
Brandts, Christian ;
Dierickx, Daan ;
Dummer, Reinhard ;
Fiorino, Gionata ;
Gornet, Jean Marc ;
Higgins, Peter ;
Katsanos, Konstantinos H. ;
Nissen, Loes ;
Pellino, Gianluca ;
Rogler, Gerhard ;
Scaldaferri, Franco ;
Szymanska, Edyta ;
Eliakim, Rami .
JOURNAL OF CROHNS & COLITIS, 2015, 9 (11) :945-965
[4]   Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis [J].
Ariyaratnam, Jonathan ;
Subramanian, Venkataraman .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (02) :163-169
[5]   Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management [J].
Berg, D ;
Otley, CC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (01) :1-17
[6]   Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease [J].
Bernklev, T ;
Jahnsen, J ;
Henriksen, M ;
Lygren, I ;
Aadland, E ;
Sauar, J ;
Schulz, T ;
Stray, N ;
Vatn, M ;
Moum, B .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (05) :402-412
[7]   Epidemiology of skin tumors: Data from the cutaneous cancer registry in Trentino, Italy [J].
Boi, S ;
Cistofolini, M ;
Micciolo, R ;
Polla, E ;
Palma, PD .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2003, 7 (04) :300-305
[8]   Changing incidence of non-melanoma skin cancer in New Zealand [J].
Brougham, Nicholas D. L. ;
Dennett, Elizabeth R. ;
Tan, Swee T. .
ANZ JOURNAL OF SURGERY, 2011, 81 (09) :633-636
[9]   LATITUDE GRADIENTS IN MELANOMA INCIDENCE AND MORTALITY IN THE NON-MAORI POPULATION OF NEW-ZEALAND [J].
BULLIARD, JL ;
COX, B ;
ELWOOD, JM .
CANCER CAUSES & CONTROL, 1994, 5 (03) :234-240
[10]   Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study [J].
de Vries, E. ;
Trakatelli, M. ;
Kalabalikis, D. ;
Ferrandiz, L. ;
Ruiz-de-Casas, A. ;
Moreno-Ramirez, D. ;
Sotiriadis, D. ;
Ioannides, D. ;
Aquilina, S. ;
Apap, C. ;
Micallef, R. ;
Scerri, L. ;
Ulrich, M. ;
Pitkanen, S. ;
Saksela, O. ;
Altsitsiadis, E. ;
Hinrichs, B. ;
Magnoni, C. ;
Fiorentini, C. ;
Majewski, S. ;
Ranki, A. ;
Stockfleth, E. ;
Proby, C. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 :1-13